https://orcid.org/0000-0002-4379-5283
References
- GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global burden of disease study 2016. Lancet Neurol. 2019;18(3):269–285.
- Ruutiainen J, Viita AM, Hahl J, et al. Burden of illness in multiple sclerosis (DEFENSE) study: the costs and quality-of-life of Finnish patients with multiple sclerosis. J Med Econ. 2016;19(1):21–33.
- European Multiple Sclerosis Platform. Under pressure. Living with multiple sclerosis in Europe; 2013. [cited 2020 Jul 30]. Available from: http://www.underpressureproject.eu/web/living-with-ms-in-europe
- Bakirtzis C, Grigoriadou E, Boziki MK, et al. The administrative prevalence of multiple sclerosis in Greece on the basis of a nationwide prescription database. Front Neurol. 2020;11:1012. Published 2020 Sep 29.
- Scalfari A, Neuhaus A, Daumer M, et al. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;85:67–75.
- Kobelt G, Kasteng F. Access to innovative treatments in multiple sclerosis in Europe. A report prepared for the European federation of pharmaceutical industry associations (EFPIA); 2009.
- Dimitrova M, Petrova G, Kamusheva M, et al. Budget and patient access analysis to second line therapy of multiple sclerosis in Bulgaria. Value Health. 2016;19(7):A428.
- Berger T, Adamczyk-Sowa M, Csépány T, et al. Management of multiple sclerosis patients in central European countries: current needs and potential solutions. Ther Adv Neurol Disord. 2018 22;11:1756286418759189.
- Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96–120.
- Yfantopoulos J, Chantzaras A. Drug policy in Greece. Value Health Regional issues. 2018;16:66–73.
- Rémuzat C, Urbinati D, Mzoughi O, et al. Overview of external reference pricing systems in Europe. J Mark Access Health Policy. 2015;10:3. DOI:10.3402/jmahp.v3.27675
- Ele P, Groot W. Cost containment measures for pharmaceuticals expenditure in the EU countries: a comparative analysis. The Open Health Serv Policy J. 2009;2:71–83.
- Kani C, Kourafalos V, Litsa P. Current environment for introducing health technology assessment in Greece. Int J Technol Assess Health Care. 2017;33(3):396–401.
- WHO. Current status of health intervention and technology assessment in the Balkan region. Document number: WHO/EURO:2020-1303-41053-55733. Available from: https://apps.who.int/iris/bitstream/handle/10665/336228/WHO-EURO-2020-1303-41053-55733-eng.pdf
- Simacek KF, Ko JJ, Moreton D, et al., The impact of disease-modifying therapy access barriers on people with multiple sclerosis: mixed-methods study. J Med Internet Res. 2018;20(10):e11168.
- Wilsdon T, Barron A, Mitchell-Heggs A, et al. Access to medicines for multiple sclerosis: challenges and opportunities. Charles River Associates; 2014. [cited 2020 Jul 30]. Available from: https://media.crai.com/sites/default/files/publications/CRA-Biogen-Access-to-MS-Treatment-Final-Report.pdf
- Essential medicines for patients with multiple sclerosis. Editorial. Lancet Neurol. 2019;18. Available from: https://www.thelancet.com/action/showPdf?pii=S1474-4422%2819%2930390-4
- Hartung DM, Bourdette DN, Ahmed SM, et al. The cost of multiple sclerosis drugs in the US and the pharmaceuticalindustry: too big to fail? Neurology. 2015;84(21):2185–2192.
- Hartung D, Alley L, Johnston K, et al. Qualitative study on the price of drugs for multiple sclerosis. Gaming the system. Neurology. 2020;94(4):e368–e375.